Eligible patients were randomly assigned ( 1:1 ) , stratified by baseline characteristics , to either low-dose eplerenone ( 50 mg/day ) or placebo , with continuation of standard antihypertensive treatment to attain therapeutic goals ( < 130/80 mm Hg ) for 52 weeks .